Tissue transglutaminase: a new target to reverse cancer drug resistance

Abstract excerpt

Cancer resistance mechanisms, which result from intrinsic genetic alterations of tumor cells or acquired genetic and epigenetic changes, limit the long-lasting benefits of anti-cancer treatments. Tissue transglutaminase (TG2) has emerged as a putative gene involved in tumor cell drug resistance and evasion of apoptosis. Although some reports have indicated that TG2 can suppress tumor growth and enhance the growth...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blood properties and coagulation
• Share to Erythrocyte Function and Pathophysiology